Consensus Statement Guides Optimal Management of EGFR-Mutation-Positive NSCLC
The 2016 consensus statement from the International Association for the Study of Lung Cancer (IASLC) describes how to best manage EGFR-mutation-positive NSCLC.
Diagnosis & Disease Information
Expression Levels of SMARCA4/BRG1 Gene Indicates Response to Chemotherapy
Significant sensitivity to cisplatin-based chemotherapy is signaled by the presence of low expression of SMARCA4/BRG1 in patients with earlier-stage NSCLC. Low expression of SMARCA4/BRG1 was also linked to a poor prognosis.
Combination of Immune Checkpoint Blockers Shows Promise in Lung Cancer
Combination therapy with durvalumab and tremelimumab demonstrated antitumor activity in 23% of 102 patients with lung cancer in a phase 1b trial, and toxicity was manageable.
Newly Approved NSCLC Diagnostic Assay Accurately Assesses for Treatment Options
An immunohistochemistry (IHC) test for rearrangements of the gene for anaplastic lymphoma kinase (ALK) receptor performed more accurately than another commonly used IHC assay, including reducing the rate of false positives.
Outcomes Are Comparable With Treatment Allocation Based on CGA or Performance Status and Age in Elderly Patients with NSCLC
Treatment allocation based on comprehensive geriatric assessment (CGA) did not improve treatment failure free survival or overall survival, but treatment toxicity was slightly reduced, in elderly patients with NSCLC.
NSCLC: Bevacizumab Beyond Disease Progression After First-line Bevacizumab
Addition of bevacizumab to chemotherapy beyond disease progression may be effective in patients with advanced non-small cell lung cancer (NSCLC).
Younger Age Linked With Targetable Genotype in NSCLC
Younger age is associated with an increased likelihood of having a targetable genotype in patients with non-small cell lung cancer (NSCLC).
SBRT Well Tolerated in Patients With Early Stage and Centrally Located NSCLC
Treatment with stereotactic body radiotherapy (SBRT) was well-tolerated by patients whose non-small cell lung cancer (NSCLC) tumors were located centrally in the chest and who were not candidates for surgery.
Rare Mutation May Extend Survival in Lung Cancer Patients With Brain Metastases
Most patients with NSCLC that has metastasized to the brain have a dire prognosis. However, researchers have identified a subset of those patients who have a rare genetic mutation and are living significantly longer than patients without the mutation.
Intensity-Modulated Radiation Lessens Side Effects for Lung Cancer Patients
An analysis of an international, cooperative-led trial of patients with locally advanced NSCLC has shown that those who received IMRT had less severe lung toxicity and were able to better tolerate their chemotherapy, compared with patients who received 3-D CRT.
- Loading...
Loading...
Loading... 
Loading...